CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY/(DEFICIT) (UNAUDITED) - USD ($)	Total	Convertible Preferred Stock [Member]	Common Stock [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Lincoln Park Purchase Agreement	Lincoln Park Purchase Agreement Common Stock [Member]	Lincoln Park Purchase Agreement Additional Paid-in Capital [Member]
Balance at Dec. 31, 2023	$ (1,348,000)		$ 5,000	$ (126,000)	$ 479,274,000	$ (480,501,000)
Balance (in shares) at Dec. 31, 2023		1,952	4,522,656
Balance, Treasury (in shares) at Dec. 31, 2023				(78,559)
Stock-based compensation	146,000				146,000
Purchase of treasury stock	(374,000)			$ (374,000)
Purchase of treasury stock (in Shares)				(179,866)
Net loss	(3,261,000)					(3,261,000)
Balance at Mar. 31, 2024	(4,837,000)		$ 5,000	$ (500,000)	479,420,000	(483,762,000)
Balance (in shares) at Mar. 31, 2024		1,952	4,522,656
Balance, Treasury (in shares) at Mar. 31, 2024				(258,425)
Balance at Dec. 31, 2023	(1,348,000)		$ 5,000	$ (126,000)	479,274,000	(480,501,000)
Balance (in shares) at Dec. 31, 2023		1,952	4,522,656
Balance, Treasury (in shares) at Dec. 31, 2023				(78,559)
Net loss	(9,075,000)
Balance at Sep. 30, 2024	(5,174,000)		$ 6,000	$ (500,000)	484,896,000	(489,576,000)
Balance (in shares) at Sep. 30, 2024		1,952	6,154,758
Balance, Treasury (in shares) at Sep. 30, 2024				(258,425)
Balance at Mar. 31, 2024	(4,837,000)		$ 5,000	$ (500,000)	479,420,000	(483,762,000)
Balance (in shares) at Mar. 31, 2024		1,952	4,522,656
Balance, Treasury (in shares) at Mar. 31, 2024				(258,425)
Stock-based compensation	151,000				151,000
Issuance of common stock	1,000		$ 1,000
Issuance of common stock (in shares)			1,439,988
Net loss	(2,940,000)					(2,940,000)
Balance at Jun. 30, 2024	(7,625,000)		$ 6,000	$ (500,000)	479,571,000	(486,702,000)
Balance (in shares) at Jun. 30, 2024		1,952	5,962,644
Balance, Treasury (in shares) at Jun. 30, 2024				(258,425)
Stock-based compensation	125,000				125,000
Exercise of pre-funded warrants (in Shares)			192,114
Reclassification of warrants to equity	5,200,000				5,200,000
Net loss	(2,874,000)					(2,874,000)
Balance at Sep. 30, 2024	(5,174,000)		$ 6,000	$ (500,000)	484,896,000	(489,576,000)
Balance (in shares) at Sep. 30, 2024		1,952	6,154,758
Balance, Treasury (in shares) at Sep. 30, 2024				(258,425)
Balance at Dec. 31, 2024	$ (8,949,000)		$ 6,000	$ (500,000)	485,024,000	(493,479,000)
Balance (in shares) at Dec. 31, 2024		1,952	6,154,758
Balance, Treasury (in shares) at Dec. 31, 2024	258,425			(258,425)
Stock-based compensation	$ 148,000				148,000
Exercise of pre-funded warrants			$ 7,000		(7,000)
Exercise of pre-funded warrants (in Shares)			6,535,731
Exercise of Series B Warrants from May 2024 PIPE	882,000				882,000
Exercise of Series B Warrants from May 2024 PIPE (in shares)			497,824
Exchange of warrants for notes payable	(3,694,000)				(3,694,000)
Issuance of common stock, pre-funded warrants and warrants for debt repayment	5,373,000		$ 4,000		5,369,000
Issuance of common stock, pre-funded warrants and warrants for debt repayment (in shares)			4,069,738
Net loss	(17,401,000)					(17,401,000)
Balance at Mar. 31, 2025	(23,641,000)		$ 17,000	$ (500,000)	487,722,000	(510,880,000)
Balance (in shares) at Mar. 31, 2025		1,952	17,258,051
Balance, Treasury (in shares) at Mar. 31, 2025				(258,425)
Balance at Dec. 31, 2024	$ (8,949,000)		$ 6,000	$ (500,000)	485,024,000	(493,479,000)
Balance (in shares) at Dec. 31, 2024		1,952	6,154,758
Balance, Treasury (in shares) at Dec. 31, 2024	258,425			(258,425)
Net loss	$ (16,673,000)
Balance at Sep. 30, 2025	$ 5,054,000		$ 132,000	$ (500,000)	515,574,000	(510,152,000)
Balance (in shares) at Sep. 30, 2025		1,952	131,863,969
Balance, Treasury (in shares) at Sep. 30, 2025	258,425			(258,425)
Balance at Mar. 31, 2025	$ (23,641,000)		$ 17,000	$ (500,000)	487,722,000	(510,880,000)
Balance (in shares) at Mar. 31, 2025		1,952	17,258,051
Balance, Treasury (in shares) at Mar. 31, 2025				(258,425)
Stock-based compensation	152,000				152,000
Exercise or exchange of March 2025 Series A and B Warrants	858,000		$ 56,000		802,000
Exercise or exchange of March 2025 Series A and B Warrants (in Shares)			56,277,032
Exercise of pre-funded warrants			$ 9,000		(9,000)
Exercise of pre-funded warrants (in Shares)			9,016,349
Cancellation of common stock (in Shares)			(300,000)
Issuance of common stock							$ 2,746,000	$ 10,000	$ 2,736,000
Issuance of common stock (in shares)								10,187,000
Reclassification of warrants to equity	10,967,000				10,967,000
Modification of warrants (Note 13)	6,801,000				6,801,000
Net loss	5,151,000					5,151,000
Balance at Jun. 30, 2025	3,034,000		$ 92,000	$ (500,000)	509,171,000	(505,729,000)
Balance (in shares) at Jun. 30, 2025		1,952	92,438,432
Balance, Treasury (in shares) at Jun. 30, 2025				(258,425)
Stock-based compensation	527,000				527,000
Exercise of March 2025 Series B Warrants (in Shares)			741,840
Exercise of pre-funded warrants			$ 8,000		(8,000)
Exercise of pre-funded warrants (in Shares)			7,767,941
Cancelled common stock			$ (3,000)		3,000
Cancellation of common stock (in Shares)			(3,472,740)
Issuance of common stock	16,850,000		$ 35,000		16,815,000
Issuance of common stock (in shares)			34,388,496
Investor fees pursuant to Support Letters (Note 13)	(2,250,000)				(2,250,000)
Liability to investors pursuant to Letter Agreement (Note 13)	(8,684,000)				(8,684,000)
Net loss	(4,423,000)					(4,423,000)
Balance at Sep. 30, 2025	$ 5,054,000		$ 132,000	$ (500,000)	$ 515,574,000	$ (510,152,000)
Balance (in shares) at Sep. 30, 2025		1,952	131,863,969
Balance, Treasury (in shares) at Sep. 30, 2025	258,425			(258,425)

PLUS THERAPEUTICS, INC. 10-Q